• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Covance Ups Guidance as Early- and Late-Stage Revenues Improve in Q2

Covance Ups Guidance as Early- and Late-Stage Revenues Improve in Q2

July 29, 2009
CenterWatch Staff

Covance reported an increase in both early- and late-stage drug development revenues for the second quarter of 2009 compared with the first quarter, but early-stage revenues remain significantly lower than the same period last year.

Early-stage net revenues were $199.8 million in the second quarter—a $7-million increase over the first quarter—but a drop from $213.1 million in Q2 2008.  The contract research organization (CRO) attributed the decrease in revenues to a lower demand in toxicology in 2009. The early-stage segment’s operating income declined 50% from the same period last year to $27.1 million.

Late-stage development revenues and income were up in the second quarter, compared with both the first quarter 2009 and Q2 of last year. Late-stage revenues grew 19% to $266.3 million, compared to $223.8 million in the second quarter 2008, and operating income increased 52.4% to $65.5 million compared to $43 million prior year.

Covance’s overall revenues climbed 6.7% from the same period last year. Revenues for the quarter were $489.2 million, compared with $461.8 million in Q2 2008. Profits for the CRO were down 15.5% to $43 million from $50.9 million in 2008. Earnings per share also fell 16% to $0.67 per share.

The company expects sequential growth to continue in the third quarter, said Covance chairman and CEO Joe Herring.

“We are upwardly adjusting our 2009 revenue growth target to the mid- to upper-single digits and our earnings per share target to a range of $2.60 to $2.80 per share (excluding gains on the sales of our centralized ECG and IVRS service lines and using June 30 exchange rates), versus our previous targets of single-digit revenue growth and earnings of $2.50 to $2.70 per share," Herring said in a company statement.  

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing